BioReference Laboratories de OPKO Health lanza un programa de pruebas para detectar la COVID-19 en escuelas de la ciudad de Nueva York

Through New York City, BioReference will be testing students, teachers and staff in nearly 1,000 NYC public schools

ELMWOOD PARK, N.J., 9 de octubre de 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school environment.

Continuing a strategic collaboration with New York City, the Department of Health, New York City Health and Hospital Corporation (NYC Health + Hospitals), the Test & Trace Corp, and the Department of Education, BioReference is performing COVID-19 molecular testing for NYC schools. In addition, BioReference is collecting specimens from principals, teachers, administration and students from over 950 schools across NYC.

“This school year for New York City and other school systems around the world is vastly different due to the global pandemic, and BioReference is privileged to aid in keeping NYC schools safe,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories.

Información acerca de BioReference Laboratories, Inc.

BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. La compañía trabaja en red con los cinco planes de salud más grandes de los Estados Unidos, dirige una red de 11 laboratorios y cuenta con el respaldo de un personal médico de más de 120 médicos, doctorados y demás clínicos y científicos de nivel profesional. Con una posición líder en las áreas de genética, salud de la mujer, medicina materno-fetal, oncología y urología, BioReference y sus laboratorios especializados, GenPath y GeneDx, están marcando el progreso en la medicina moderna. Para obtener más información, visite www.bioreference.com.

Información acerca de OPKO Health, Inc.

OPKO es una compañía biofarmacéutica y de diagnóstico multinacional que busca posicionarse como líder de la industria en grandes mercados de rápido crecimiento, a través de sus tecnologías exclusivas y su experiencia e innovación en el descubrimiento, el desarrollo y la comercialización. For more information, visit www.opko.com.

Advertencia respecto de declaraciones con perspectivas de futuro

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding the role COVID-19 testing will play in supporting a safer classroom environment, the accuracy and availability of the test and the role and value of the information provided and its impact on decisions relative to the safety of educators, students and their families, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in its other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contacto de BioReference Laboratories para los medios:
Hillary Titus, htitus@bioreference.com   

Powered by Translations.com GlobalLink OneLink Software